News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Altimmune (ALT) had its "sell (d-)" rating reaffirmed by Weiss Ratings.

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.

Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.

Altimmune Touts Pemvidutide Progress, Targets MASH Phase 3 Start and Q3 AUD Readout at Barclays Chat [Yahoo! Finance]

3/5/2026

07:00 am

alt

-17.1%

MISS

11/6/2025

07:00 am

alt

4.2%

BEAT

8/12/2025

07:00 am

alt

2.9%

BEAT

5/13/2025

07:00 am

alt

-3.7%

BEAT

Form 4 Altimmune, Inc. For: Apr 06 Filed by: GILL JOHN

Form 4 Altimmune, Inc. For: Apr 01 Filed by: Durso Jerome Benedict

Form 4 Altimmune, Inc. For: Apr 01 Filed by: WEAVER GREGORY L

Form SCHEDULE 13G/A Altimmune, Inc. Filed by: VANGUARD GROUP INC

Form ARS Altimmune, Inc. For: Dec 31

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}